Back to results
US 12,674,150 B2Granted
Target-specific CRISPR mutant
AssigneeToolgen Incorporated
InventorsJoon Sun Lee, Min Hee Jung, Yu Ri Choi, Jeong Joon Lee
Life of this patent
Estimating the term…
Abstract
The present invention relates to an artificially engineered CRISPR/Cas9 system. More particularly, the present invention relates to an artificially engineered CRISPR enzyme having enhanced target specificity and a use of an artificially engineered CRISPR/Cas9 system including the same enzyme in genome and/or epigenome manipulation or modification, genome targeting, genome editing, and in vitro diagnosis, etc.
Claims13
A SpCas9 (Streptococcus pyogenes Cas9) variant of SEQ ID NO:
- 17,
- wherein the variant consists of the following mutations:
- substitution of aspartic acid at 10th position (D10) or histidine at 840th position (H840) of SEQ ID NO:
- 17 with alanine;
- substitution of phenylalanine at 539th position (F539) of SEQ ID NO:
- 17 with serine;
- substitution of methionine 763rd position (M763) of SEQ ID NO:
- 17 with isoleucine;
- substitution of lysine 890th position (K890) of SEQ ID NO:
- 17 with asparagine;
- and
- substitution of glutamic acid at 1007th position (E1007) of SEQ ID NO:
- 17 with one amino acid selected from the group consisting of alanine, asparagine, aspartic acid, glutamine, glycine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine.
10 more elements
Dependencies are inferred from the claim text.